Purpose: To explore the benefit yielded by radiotherapy (RT), we report a series of metastatic renal cell carcinoma (RCC) patients treated with concomitant RT plus Nivolumab. Methods/patients: Patients undergoing Nivolumab treatment plus concomitant RT (ablative or palliative) were included. RT was defined Ablative if >5 Gy/fraction were delivered. Results: Ablative RT intent was the only independent predictor of both progression free and overall survival (HR 3.51, 95% CI 1.6–7.5, p = 0.0012 and HR 2.8, 95% CI 0.99–8.07, p = 0.05, respectively). Conclusion: Ablative RT may improve oncologic outcomes in selected patients with metastatic RCC treated with Nivolumab as compared to palliative RT.
Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience / Francolini G.; Campi R.; Di Cataldo V.; Detti B.; Loi M.; Triggiani L.; La Mattina S.; Borghetti P.; Magrini S.M.; Nicosia L.; Alongi F.; Ghirardelli P.; Vavassori V.; Allegra A.G.; Aquilano M.; Scoccimarro E.; Peruzzi A.; Pastina P.; Visani L.; Desideri I.; Serni S.; Meattini I.; Livi L.. - In: CLINICAL & TRANSLATIONAL ONCOLOGY. - ISSN 1699-048X. - ELETTRONICO. - 24:(2022), pp. 2039-2043. [10.1007/s12094-022-02844-5]
Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience
Francolini G.;Campi R.;Di Cataldo V.;Detti B.;Loi M.;Magrini S. M.;Aquilano M.;Scoccimarro E.;Peruzzi A.;Desideri I.;Serni S.;Meattini I.;Livi L.
2022
Abstract
Purpose: To explore the benefit yielded by radiotherapy (RT), we report a series of metastatic renal cell carcinoma (RCC) patients treated with concomitant RT plus Nivolumab. Methods/patients: Patients undergoing Nivolumab treatment plus concomitant RT (ablative or palliative) were included. RT was defined Ablative if >5 Gy/fraction were delivered. Results: Ablative RT intent was the only independent predictor of both progression free and overall survival (HR 3.51, 95% CI 1.6–7.5, p = 0.0012 and HR 2.8, 95% CI 0.99–8.07, p = 0.05, respectively). Conclusion: Ablative RT may improve oncologic outcomes in selected patients with metastatic RCC treated with Nivolumab as compared to palliative RT.
| File | Dimensione | Formato | |
|---|---|---|---|
|
s12094-022-02844-5.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
838.96 kB
Formato
Adobe PDF
|
838.96 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
